AstraZeneca stock gains on lung cancer trial news
Published on 08/17/2026 at 17:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock rose after late-stage lung cancer trial updates and a decision to stop one experimental study, with U.S.-listed shares last seen at $156.72 on August 17, 2026. The same market snapshot showed a $244.09 billion market cap and an intraday range of $156.58 to $157.00, while the latest Reuters-linked market report said the London listing gained 0.9% on the trial news.
Trial headlines drive the tape
The catalyst centers on phase III lung cancer data, where recent reporting said two trial updates supported the oncology franchise and another report said volrustomig testing was being stopped after it did not look stronger than existing therapies. Those headlines helped lift the shares by 0.9% in London and by as much as 1.4% in U.S.-focused market coverage.
For investors, the immediate read-through is that AstraZeneca's cancer pipeline remains the main valuation lever. The market is reacting to trial execution, not to a new pricing story or a broad portfolio re-rating.
What the latest numbers say
Market data on August 17, 2026 put the U.S. listing at $156.72, with a 52-week view that included a low near $107.84 and a high of $157.32 on the London quote page. The U.S. market snapshot also showed a dividend yield of 2.00% and a P/E ratio of 23.22.
Recent consensus snapshots in market coverage pointed to an average price target of $211.68 and another consensus view of $211.00, implying a gap of more than 35 percent from the last U.S. price shown in the same set of market pages. That spread matters because it shows how much future growth is already embedded in the oncology and rare-disease pipeline.
Oncology remains the core
The product story is still anchored by Enhertu, the antibody-drug conjugate developed with Daiichi Sankyo and tied to late-stage lung cancer work. The latest trial headline around that program is why the market treated the release as more than routine pipeline noise.
Price and valuation
As of August 17, 2026, AstraZeneca shares were quoted at $156.72 on the U.S. listing, with the same session showing a market cap of $244.09 billion and an intraday move between $156.58 and $157.00. The shares remain close to the upper end of the quoted annual range and well above the low seen in the same set of market data.
Fact box
Company: AstraZeneca PLC
ISIN: US6549022043
Ticker: AZN
Exchange: New York Stock Exchange
Price (as of August 17, 2026, 12:58 p.m. ET): $156.72 USD
Market cap: $244.09 billion (as of August 17, 2026)
Sector / Industry: Healthcare / Pharmaceuticals
Index membership: FTSE 100
